Validation of an ICD ‐10 case‐finding algorithm for endometrial cancer in US insurance claims
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Djeneba Audrey Djibo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Safety, Surveillance & Collaboration, CVS Health, Blue Bell, Pennsylvania, USA. Hauptthemen laut MEDLINE: International Classification of Diseases, Endometrial Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TherapeuticsMD.
Abstract (Originalsprache)
Purpose
To evaluate the positive predictive value (PPV) of an endometrial cancer case finding algorithm using International Classification of Disease 10th revision Clinical Modification (ICD‐10‐CM) diagnosis codes from US insurance claims for implementation in a planned post‐marketing safety study. Two algorithm variants were evaluated.
Methods
Provisional incident endometrial cancer cases were identified from 2016 through 2020 among women aged ≥50 years. One algorithm variant used diagnosis codes for malignant neoplasms of uterine sites (C54.x), excluding C54.2 (malignant neoplasm of myometrium); the other used only C54.1 (malignant neoplasm of endometrium). A random sample of medical records of recent incident provisional cases (2018–2020) was requested for adjudication. Confirmed cases showed biopsy evidence of endometrial cancer, documentation of cancer staging, or hysterectomy following diagnosis. We estimated the PPV of the variants with 95% confidence intervals (CI) excluding cases that had insufficient information.
Results
Of 294 provisional cases adjudicated, 85% were from outpatient settings ( n = 249). Mean age at diagnosis was 69.3 years. Among the 294 adjudicated cases (identified with the broader algorithm variant), the same 223 were confirmed endometrial cancer cases by both algorithm variants. The PPV (95% CI) for the broader algorithm variant was 84.2% (79.2% and 88.3%), and for the variant using only C54.1 was 85.8% (80.9% and 89.8%).
Conclusion
We developed and validated an algorithm using ICD‐10‐CM diagnosis codes to identify endometrial cancer cases in health insurance claims with a sufficiently high PPV to use in a planned post‐marketing safety study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Safety, Surveillance & Collaboration, CVS Health, Blue Bell, Pennsylvania, USA.
- Epidemiology, RTI Health Solutions, Barcelona, Spain.
- Epidemiology, RTI Health Solutions, Waltham, Massachusetts, USA.
- Medical Policy Operations, Aetna, CVS Health, Cleveland, Ohio, USA.
- TherapeuticsMD, Boca Raton, Florida, USA.
ORCID-Profile: Djeneba Audrey Djibo, Andrea V Margulis, Cheryl N McMahill-Walraven, Catherine W Saltus, James A Kaye, Catherine B Johannes
Förderung
- TherapeuticsMD
Zitieren
APA
Djibo, D. A., Margulis, A. V., McMahill-Walraven, C. N., Saltus, C. W., Shuminski, P., Kaye, J. A., Johannes, C. B., Libertin, M., & Graham, S. (2024). Validation of an ICD ‐10 case‐finding algorithm for endometrial cancer in US insurance claims. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5690
Vancouver
Djibo DA, Margulis AV, McMahill-Walraven CN, Saltus CW, Shuminski P, Kaye JA, et al. Validation of an ICD ‐10 case‐finding algorithm for endometrial cancer in US insurance claims. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5690
BibTeX
@article{Djibo2024,
author = {Djibo, Djeneba Audrey and Margulis, Andrea V and McMahill-Walraven, Cheryl N and Saltus, Catherine W and Shuminski, Patricia and Kaye, James A and Johannes, Catherine B and Libertin, Mark and Graham, Shelli},
title = {Validation of an ICD ‐10 case‐finding algorithm for endometrial cancer in US insurance claims},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5690}
}
EUVIMED